Lab Manager | Run Your Lab Like a Business

Product News

Custom AAV Enable Targeted Gene Delivery

AMSBIO's robust Adeno-Associated Virus production service provides researchers with high quality vectors

Computer image of AAV in a medium

As a leading expert in AAV technology, AMSBIO’s custom production service is set-up to help you design, clone, and/or viral package your custom AAV construct.

by AMSBIO
Register for free to listen to this article
Listen with Speechify
0:00
5:00

AMSBIO is a leading provider of ready-to-use Adeno-Associated Virus (AAV) that can be engineered to efficiently deliver specific DNA sequences into target cells with a low immunogenicity. 

Drawing upon years of experience—AMSBIO have developed a robust AAV Production Service providing researchers with access to the highest quality recombinant AAV vectors that can efficiently transfect multiple cell types, including dividing and non-dividing cells. These AAV vectors induce persistent gene expression in vivo without integrating into the host genome or causing any disease. These features make AAV an exciting platform for gene delivery enabling treatment of a variety of human diseases including cancer. There are already preclinical and clinical successes in AAV-mediated gene replacement, gene silencing, and gene editing.

As a leading expert in AAV technology, AMSBIO’s custom production service is set-up to help you design, clone, and/or viral package your custom AAV construct. As part of their production service, AMSBIO offers a range of AAV serotypes (1-9, DJ) that differ in their tropism, or the types of cells they infect, allowing the company to preferentially transduce specific cell types.

Starting from customer provided target templates, a sequence from a cDNA collection, a custom synthesized DNA sequence, or shRNA—AMSBIO constructs the AAV clone and generates ready-to-use expression AAV. As part of the production service—AMSBIO sub-clones your selected genes into their AAV expression vectors and produces expression AAV for each gene.